Literature DB >> 19593574

[Pulmonary arterial hypertension in collagenoses].

M Claussen1, G Riemekasten, M M Hoeper.   

Abstract

Pulmonary arterial hypertension is a rare disease of small pulmonary arteries of unknown origin characterised by endothelial dysfunction and cellular proliferation throughout all vessel layers, resulting in progressively elevated pulmonary arterial resistance with increasing right heart strain and finally right heart failure. The condition may develop in connective tissue diseases with variable frequency leading to a substantial worsening of prognosis. However, the spectrum of therapeutic options has broadened significantly in recent years. Several compounds have gained approval that act mainly as pulmonary vasodilators. Further drugs are under investigation, some of which target pulmonary vascular remodeling. Echocardiography remains the primary examination for disease detection. To classify pulmonary hypertension definite hemodynamic evaluation by means of right heart catheterisation and a thorough differential diagnosis are essential to provide the basis for further treatment. For differential therapy and assessment of follow-up profound knowledge is required, pointing to the need for close cooperation with specialised centres.

Entities:  

Mesh:

Year:  2009        PMID: 19593574     DOI: 10.1007/s00393-009-0480-0

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  65 in total

1.  Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.

Authors:  Micah R Fisher; Stephen C Mathai; Hunter C Champion; Reda E Girgis; Traci Housten-Harris; Laura Hummers; Jerry A Krishnan; Fredrick Wigley; Paul M Hassoun
Journal:  Arthritis Rheum       Date:  2006-09

2.  Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

Authors:  C P Denton; M Humbert; L Rubin; C M Black
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

3.  Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension.

Authors:  Micah R Fisher; Paul R Forfia; Elzbieta Chamera; Traci Housten-Harris; Hunter C Champion; Reda E Girgis; Mary C Corretti; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2009-01-22       Impact factor: 21.405

4.  Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.

Authors:  V V McLaughlin
Journal:  Eur J Clin Invest       Date:  2006-09       Impact factor: 4.686

5.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease.

Authors:  David B Badesch; Nicholas S Hill; Gary Burgess; Lewis J Rubin; Robyn J Barst; Nazzareno Galiè; Gerald Simonneau
Journal:  J Rheumatol       Date:  2007-11-01       Impact factor: 4.666

6.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Authors:  Gérald Simonneau; Lewis J Rubin; Nazzareno Galiè; Robyn J Barst; Thomas R Fleming; Adaani E Frost; Peter J Engel; Mordechai R Kramer; Gary Burgess; Lorraine Collings; Nandini Cossons; Olivier Sitbon; David B Badesch
Journal:  Ann Intern Med       Date:  2008-10-21       Impact factor: 25.391

7.  Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing.

Authors:  Roland Wensel; Christian F Opitz; Stefan D Anker; Jörg Winkler; Gert Höffken; Franz X Kleber; Rakesh Sharma; Manfred Hummel; Roland Hetzer; Ralf Ewert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

8.  Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

Authors:  A M Stupi; V D Steen; G R Owens; E L Barnes; G P Rodnan; T A Medsger
Journal:  Arthritis Rheum       Date:  1986-04

9.  Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

Authors:  M Humbert; E S Segal; D G Kiely; J Carlsen; B Schwierin; M M Hoeper
Journal:  Eur Respir J       Date:  2007-05-15       Impact factor: 16.671

10.  Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.

Authors:  D Mukerjee; D St George; B Coleiro; C Knight; C P Denton; J Davar; C M Black; J G Coghlan
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

View more
  1 in total

Review 1.  [Systemic lupus erythematosus. A problem based approach].

Authors:  S Kleinert; M Feuchtenberger; H-P Tony
Journal:  Internist (Berl)       Date:  2010-08       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.